NASHVILLE, TENNESSEE / ACCESS Newswire / November 20, 2025 / CenExel, a leading network of clinical research sites, is hosting a two-day Good Clinical Practice (GCP) training initiative beginning ...
13h
Why Analysts Say the CytomX Story Is Evolving After Recent Clinical Momentum and Price Target Hike
CytomX Therapeutics has recently seen its consensus analyst price target rise from $6.14 to $7.07 per share, reflecting growing optimism about the company’s outlook as its lead asset moves forward in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback